Identification of a novel linear B-cell epitope in the UL26 and UL26.5 proteins of Duck Enteritis Virus by Liu, Xiaoli et al.
RESEARCH Open Access
Identification of a novel linear B-cell epitope in
the UL26 and UL26.5 proteins of Duck Enteritis
Virus
Xiaoli Liu, Zongxi Han, Yuhao Shao, Dan Yu, Huixin Li, Yu Wang, Xiangang Kong
*, Shengwang Liu
*
Abstract
Background: The Unique Long 26 (UL26) and UL26.5 proteins of herpes simplex virus are known to function
during the assembly of the viruses. However, for duck enteritis virus (DEV), which is an unassigned member of the
family Herpesviridae, little information is available about the function of the two proteins. In this study, the C-
terminus of DEV UL26 protein (designated UL26c), which contains the whole of UL26.5, was expressed, and the
recombinant UL26c protein was used to immunize BALB/c mice to generate monoclonal antibodies (mAb). The
mAb 1C8 was generated against DEV UL26 and UL26.5 proteins and used subsequently to map the epitope in this
region. Both the mAb and its defined epitope will provide potential tools for further study of DEV.
Results: A mAb (designated 1C8) was generated against the DEV UL26c protein, and a series of 17 partially
overlapping fragments that spanned the DEV UL26c were expressed with GST tags. These peptides were subjected
to enzyme-linked immunosorbent assay (ELISA) and western blotting analysis using mAb 1C8 to identify the
epitope. A linear motif,
520IYYPGE
525, which was located at the C-terminus of the DEV UL26 and UL26.5 proteins,
was identified by mAb 1C8. The result of the ELISA showed that this epitope could be recognized by DEV-positive
serum from mice. The
520IYYPGE
525 motif was the minimal requirement for reactivity, as demonstrated by analysis
of the reactivity of 1C8 with several truncated peptides derived from the motif. Alignment and comparison of the
1C8-defined epitope sequence with those of other alphaherpesviruses indicated that the motif
521YYPGE
525 in the
epitope sequence was conserved among the alphaherpesviruses.
Conclusion: A mAb, 1C8, was generated against DEV UL26c and the epitope-defined minimal sequence obtained
using mAb 1C8 was
520IYYPGE
525. The mAb and the identified epitope may be useful for further study of the
design of diagnostic reagents for DEV.
Background
Herpesviruses exist widely in nature. The genomes of
herpesviruses consist of linear double-stranded DNA;
they differ in size (from approximately 124 to 235 kb),
sequence arrangement and base composition [1], and
vary significantly with respect to the presence and
arrangement of inverted and directly repeated
sequences. The genomes of most of the alphaherpes-
viruses, such as herpes simplex virus 2 (HSV-2) [2] and
Marek’s disease virus 1 (MDV-1) [3], encode more than
70 proteins; some of these proteins are not essential for
the replication of the viruses. Only limited information
is available about the structures and functions of these
70 proteins, although some studies of the antigenic
determinants of the glycoproteins have been reported
[4,5]. Three types of capsid, named A-, B-, and C-cap-
sids, are needed in the assembly of HSV-1 [6]. B-capsids
lack DNA but may be the important intermediates in
virus assembly [7-10]. The unique feature of B-capsids
is the presence of an abundant core protein, named
scaffolding protein ICP35 (VP22a) [6,11-13], which is
encoded by the in-frame gene UL26.5.T h i sp r o t e i n
is present in the B-capsids of the HSV-1 assembly but is
absent after the completion of DNA encapsidation and
is not found in the mature virion [14].
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the family Herpesviridae [15], is the cause of duck viral
enteritis (DVE), which is also known as duck plague
(DP), a disease of Anseriformes.D V Ei saf o r mo f
hemorrhagic enteritis that occurs in captive or free-fly-
ing waterfowl [16] and causes heavy economic losses in
commercial duck production [17]. The DEV establishes
an asymptomatic carrier state in waterfowl in the course
of infection, and it is only detectable during the inter-
mittent shedding period of the infection [18]. Currently,
only limited information is available on the genomic
sequence and encoded proteins of DEV; therefore the
development of diagnostic methods based on virus
detection is difficult. Hence, the development of immu-
nity based prophylactic, therapeutic, and diagnostic
techniques for the control DEV is of significance.
The DEV has a linear double-stranded DNA genome
of approximately 180 kb with a G+C content of 64.3%
[16]. The genes and their arrangements in the DEV UL
region have been reported by our laboratory [19-23].
Our results have demonstrated that DEV UL26 and
UL26.5, two nested in-frame genes, encode a capsid
maturation protease and the minor capsid scaffold pro-
tein of DEV [20].
B-cell epitopes are antigenic determinants that are
recognized and bound by membrane-associated recep-
tors on the surface of B lymphocytes [24]. They can be
classified into two types: linear (continuous) epitopes
and conformational (discontinuous) epitopes. Linear epi-
topes are short peptides that correspond to a contiguous
amino acid sequence within a protein [25,26]. To date,
there has been no study of the B-cell epitopes of DEV.
In this study, we first expressed the 360 amino acids in
the C-terminus of the DEV UL26 protein (named
UL26c), which contain the whole sequence of UL26.5.
Subsequently, we generated a monoclonal antibody
(mAb) (named 1C8) against DEV UL26 by vaccination
of mice with a recombinant UL26c prime and DEV par-
ticle boost. Finally, we identified an epitope in the DEV
UL26 protein which was recognized by the mAb 1C8.
These results will provide a basic understanding of the
structure, function and localization of the DEV UL26
protein and UL26.5 protein. This mAb and the recombi-
nant proteins could be used as a potential tool for the
design of diagnostic reagents for DEV.
Results
Production of the recombinant protein UL26c
Owing to the difficulty of expressing the whole UL26
gene (in total 2124 bp in length) of DEV, we used pro-
karyotic expression of the C-terminal 360-amino acid
(348-707aa) protein in E. coli BL21 (DE3) after induc-
tion by Isopropyl-b-D-thiogalactopyranoside (IPTG) and
termed the recombinant protein UL26c. Western
blotting using murine antibody against DEV showed
that UL26c could react with DEV antibody (Figure 1A),
which implied that it had similar antigenicity to native
DEV UL26 protein. The UL26c was used to prime
immunity and DEV particles were used as boost anti-
gens to prepare the mAb.
Generation of mAb against the DEV UL26 protein
One hybridoma clone that secreted mAb specific to the
DEV UL26 protein was selected and designated as 1C8.
The subclass of 1C8 was determined to be IgM with 
light chain. Both western blotting and ELISA showed
that 1C8 could react specifically with both chicken
embryonic fibroblasts (CEF) infected with DEV (Figure
1B and Figure 1C) and the recombinant protein UL26c
(Figure 1D and Figure 1C). In summary, we can con-
clude that the mAb 1C8 recognized the DEV UL26 pro-
tein specifically.
Mapping and identification of the epitope of UL26
protein
For fine mapping of the epitope of DEV UL26 that was
recognized by mAb 1C8, a set of GST fused proteins
(Figure 2) were expressed in prokaryotes and used
together to identify the epitope by both western blotting
and ELISA. Western blotting showed that the peptide
F2 (432-577aa) was recognized by mAb 1C8 (Figure
3A). The further screening results showed that both F2-
2 (471-525aa) and F2-3 (511-577aa) could react with
mAb 1C8, while F2-1 (432-485aa) failed to be recog-
nized (Figure 3A). These results indicated that the over-
lapping sequence shared by F2-2 and F2-3 may contain
the epitope recognized by mAb 1C8. Hence, to define
the epitope defined by mAb 1C8 in the UL26 protein
more precisely, a series of truncated peptides (from F4
to F 14; Figure 2) that were deleted successively from
the amino or carboxyl terminuses of the overlapping
fragment were expressed, respectively, for subsequent
screening of mAb 1C8. The results showed that the
mAb 1C8 reacted with peptides from F4 (511-525aa) to
F12 (520-525aa) (Figure 3B and Figure 3C), but not with
F13 (519-524aa) and F14 (521-525aa) (Figure 3C).
Therefore, we considered that the motif
520IYYPGE
525 is
the defined minimal epitope in the UL26 protein of the
DEV Clone-03 strain that is recognized by mAb 1C8,
because deletion of I
520 or E
525 destroyed the binding of
the GST fusion peptides by mAb 1C8. In addition, the
results were confirmed further by ELISA (Figure 3D).
Reaction of the epitope peptide with duck anti-DEV
antibody
The recombinant peptide, F12 (
520IYYPGE
525), was used
as an antigen to react with mouse anti-DEV antibody in
this study. The results of both western blotting and
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could react with murine anti-DEV antibody (Figure 4),
which demonstrated that the epitope had good reactivity.
Alignment of the 1C8-defined sequences in
alphaherpesviruses
The mAb 1C8-defined motif and flanking sequences in
the UL26 protein of alphaherpesviruses were aligned
and analyzed. The results showed that the epitope
defined by mAb 1C8,
520IYYPGE
525, was relatively con-
served in alphaherpesviruses (Figure 5). Interestingly,
EHV-1 and EHV-4 have the same amino acid residues
as DEV in the motif defined by mAb 1C8. Two residues
of the epitope,
521YY
522, were highly conserved among
the alphaherpesviruses, except for the residue F
521 in
VZV. In addition, the C-terminus of the amino acids of
the epitope was highly conserved among most of the
alphaherpesviruses selected for this study (Figure 5).
Discussion
Formation of the herpesvirus capsid is the first step in
viral morphogenesis. The capsid of HSV-1 is found in
t h em a t u r ev i r i o n sa n di nt h enuclei of infected cells
from which they originate. There are three distinct types
of capsid, A-, B- and C-capsids, in infected cells [6]. The
B-capsids of HSV-1 contain a large amount of the scaf-
folding protein (the product of the UL26.5 gene), and
smaller amounts of VP24 and VP21, the products of the
UL26 gene. The UL26 and UL26.5 genes are expressed
as 3’-coterminal transcripts, and the promoter for the
UL26.5 gene is located within the coding region of the
UL26 gene in HSV-1 [27-29]. The UL26 gene encodes a
self-cleaved protease that generates the capsid proteins
VP21 and VP24 [30]. Cleavage of the UL26 and UL26.5
proteins is not required for capsid assembly, but the
cleavage event is essential for DNA encapsidation [31].
The UL26.5 gene encodes the scaffold protein VP22a
[27], which has been linked to a family of proteins
named infected-cell protein 35 (ICP35). The VP22a is
the most abundant protein found in the B-capsid and
may form the scaffold of the HSV-1 B-capsid [32]. The
B-capsid is similar to the capsid found in infectious
HSV-1 particles, except that it lacks DNA. The cavity of
the B-capsid is occupied instead by a proteinaceous core
Figure 1 Reactivity of mAb 1C8 with DEV and recombinant UL26c protein by western blotting and ELISA. A) The western blotting results
showed the reactivity of recombinant protein UL26c with murine anti-DEV serum; E. coli BL 21 (DH3) without induction was used as a negative
control. B) Western blotting results showed the reactivity of CEF infected with DEV with mAb 1C8; normal CEF were used as negative controls.
C) The ELISA results showed the reactivities of DEV in CEF with mAb 1C8 and the recombinant protein UL26c with mAb 1C8; SPF mouse sera
were used as negative controls. D) The recombinant protein UL26c was probed with mAb 1C8. E. coli BL 21 (DH3) without induction was used
as a negative control.
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Figure 2 Schematic diagram showing the truncated fragments derived from the UL26c protein of DEV Clone-03 strain and their
relative positions. Letters represent the amino acid positions in the UL26 protein. The names of the peptides are as in Table 1. The bars
represent peptides of the truncated DEV UL26 proteins. The peptides that were negative in western blotting and ELISA with mAb 1C8 are
shown in gray and the peptides that were positive in western blotting and ELISA with mAb 1C8 are shown in pink.
Figure 3 Precise localization of the epitope defined by mAb 1C8. The reactivity of mAb 1C8 with different truncated recombinant proteins
was determined by western blotting and ELISA. The names of the proteins are the same as in Table 1. Recombinant GST (rGST) protein was
used as a negative control in both the western blotting and indirect ELISA. A) The western blotting results of mAb 1C8 with peptides F1, F2, F3,
F2-1, F2-2 and F2-3. B) The western blotting results of mAb 1C8 with peptides F4, F5, F6, F7, F8, F9 and F10. C) The western blotting results of
mAb 1C8 with peptides F11, F12, F13 and F14. D) The results of ELISA of mAb 1C8 with the 17 recombinant proteins. The pink columns
indicated the results of the ELISA of mAb 1C8 with the 17 recombinant proteins and the green columns are negative controls, which showed
the results of ELISA of SP2/0 cell culture media with the recombinant proteins.
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teinase cleaves the products of the UL26.5 gene, and
itself, at a site 25 amino acids from the C terminus of
its product [27]. DEV is an unassigned member in the
family Herpesviridae and, to date, there has been no
report of the structure and function of proteins UL26
and UL26.5 in DEV. It has been reported that the genes
UL26 and UL26.5 in DEV are similar to their homolo-
gues in other alphaherpesviruses [20]. It has been specu-
lated that they have similar functions in viral infection
and replication to those of HSV-1 and other
alphaherpesviruses.
In this study, we expressed the C-terminus of DEV
UL26 and immunized mice with both recombinant pro-
tein UL26c and the DEV particles, using a prime-boost
protocol, and one mAb (1C8) was generated by cell
fusion. Interestingly, six bands were detected in DEV-
infected CEFs in western blotting analysis using mAb
1C8 in this study (Figure 1B). These may have origi-
nated from cleavage by the products of the UL26 gene.
Figure 6 shows the proteins that are predicted to origi-
nate from the products of the DEV UL26 and UL26.5
by the alignment of the homologous in HSV-1. The
DEV UL26 gene encodes a deduced protein of 707
amino acids [20]. Comparison of the amino acids in
DEV UL26 with the homologous in HSV-1 showed that
DEV UL26 contains two sites. The release site (R) was
at amino acids 281 and 282, and the maturational site
(M) was at amino acids 677 and 678. Self-cleavage by
UL26 may yield the proteolytically active VP24-like pro-
tein and VP21-like protein (Figure 6) [30], which are
approximately 31 kD and 43 kD, respectively. The
UL26.5 gene is in frame with UL26; therefore, the
UL26.5-encoded proteins possess the same M site as the
Figure 4 Reactivity of the identified epitope (F12:
520IYYPGE
525) with antibodies against DEV. A) The peptide that corresponded to the
epitope defined by mAb 1C8 was used as the coating antigen in an ELISA, and purified rGST protein was used as a negative control. The
murine anti-DEV antibody was used as the primary antibody and SPF mouse sera were used as negative antibody controls. B) The western
blotting results of the epitope defined by mAb 1C8 with the murine antibody against DEV; the rGST and E. coli BL 21 (DH3) without induction
were used as negative controls.
DDQLDGDN------IYYPGESVYLG---RGSIRGGQQPL
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DANTRDDIEG----IYYPGER--S---PRPVER------
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DQRELDS--------FYSGES--------QMDG------
DHPRGRSGGGDDDEAYYPGEG--A---PAELPP------
EPLRSRGGG--DDEAYYPGEG--A---PAELPP------
DQDEPDA-----DYPYYPGEARGA---PRGVDS------
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DYDDRD------DAPYYPGEARAP---PRVVPDSGGRGR
DHDDRD------DAAYYPGEARAP----RFAPDSAG--R
DRSIESD-------LYYPGEFRRSNFSPPQASSMKYEET
DKSPEQE-------PYYPGEFQQS-----EHRNLRCEDG
DKYDEPD-------LYYPGELSRH--EPHYEGEGKNVGP
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Figure 5 Alignment of the sequences in the epitope motif with
14 herpesviruses in subfamily Alphaherpesvirinae. The epitope
sequences are underlined and the amino acid residues in the
epitope region that are shared by different herpesviruses are shown
in red. Hyphens indicated the deleted amino acid residues. EHV:
equine herpesvirus; PRV: pseudorabies virus; VZV: varicella-zoster
virus; BHV: bovine herpesvirus; HSV: herpes simplex virus; CeHV:
cercopithecine herpesvirus; MDV: Marek’s disease virus; HVT: turkey
herpesvirus; ILTV: infectious laryngotracheitis virus.
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six bands detected using western blotting in this study
may indicate the six products of UL26 and UL26.5.
A series of 17 fragments that spanned the UL26c pro-
tein were expressed with a GST tag in this study, and
used to screen for the minimal epitope recognized by
mAb 1C8 using western blotting and ELISA. It was
demonstrated that the minimal sequence of the epitope
defined by mAb 1C8 appeared to be
520IYYPGE
525,
because any deletion of residues from either end of
520IYYPGE
525 destroyed the ability of mAb 1C8 to bind.
Comparative analysis of the amino acid sequences of
the identified epitope with those of another 14 alpha-
herpesviruses revealed that the C-terminus of the linear
B-cell epitope
521YYPGE
525 is conserved among the
selected alphaherpesviruses, except PRV, VZV and
ILTV. It has been reported previously that the motif
YYPGE is conserved in the scaffold proteins of alpha-
herpesviruses [33]. It was reported that deletion of a 9-
amino acid motif from the HSV-1 UL26.5, comprising
amino acids 143 to 151, which contained the sequence
YYPGE, did not affect the formation of capsids in vitro
but had a specific effect on incorporation of the portal.
This indicated that this deletion had blocked DNA
packing but had not interfered with the assembly of B-
capsids [33,34]. Therefore, the 9-amino acid motif that
contains YYPGE is required for the formation of portal-
containing capsids in HSV-1-infected cells, and it is
essential for the production of infectious virus [34].
However, in DEV, the function of the motif needs
further investigation.
The result of the in vitro neutralization test showed
that mAb 1C8 could not neutralize the infectivity of
DEV. The absence of neutralizing activity against DEV
might indicate that this region has low immunogenicity
or, more probably, that this region is not exposed on
the surface of the virion. Indeed, the products of the
HSV-1 UL26 gene are components of viral capsids,
which are located inside of the viral tegument and
envelope, while the products of the UL26.5 gene are
components of B-capsids [28]. The products encoded by
the two genes show predominantly nuclear localization
within infected cells [35]. The B-capsids are accumu-
lated in the nucleus prior to viral DNA encapsidation
[36] and the predominant component of B-capsids is
the product of the UL26.5 gene, which also contains the
sequences of the epitope defined by 1C8.
The mAb 1C8 and its epitope, which was defined in
this study, may prove to be very useful tools for the
development of immunity-based therapeutic and diag-
nostic techniques for DEV, although the mAb lacked
neutralizing ability.
Conclusion
In this study, we generated a mAb, 1C8, and identified a
novel linear B-cell epitope on the DEV UL26 and
UL26.5 proteins using this mAb. The identified epitope
and mAb 1C8 may increase our understanding of the
function and location of the UL26 and UL26.5 proteins
in DEV. It will also be a potential tool for the design of
diagnostic reagents for DEV.
Methods
Cells and virus strain
The SP2/0 cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) (Invitrogen, USA) supplemen-
ted with 10% fetal bovine serum (FBS) (Invitrogen,
USA) and 1% penicillin-streptomycin in a humidified 5%
CO2 atmosphere at 37°C. Chicken embryo fibroblasts
(CEF) were prepared from 9- to 11-day-old specific-
pathogen-free (SPF) embryonated eggs according to
standard procedures. The DEV Clone-03 strain was pur-
ified from a commercial Chinese DEV vaccine using the
plaque assay, as described previously [19]. The virus was
propagated in CEF in DMEM with 8% FBS and har-
vested when the cytopathic effect (CPE) reached 80%.
After three freeze-thaw cycles, cell lysates were con-
firmed primarily by electron microscopy (JEM-1200 EX,
Japan) and polymerase chain reaction (PCR) [20].
Gene cloning, construction of recombinant expression
vectors and expression of fusion proteins
Given that it is difficult to induce prokaryotic expression
of the full UL26 gene, we expressed a fragment of 1083
bp at the C-terminus of the DEV UL26 gene (UL26c)b y
Met
R-site
A-281/S-282 A-677/S-678
M-site
UL26
UL26.5
UL26/677
UL26/281
UL26/281/677
UL26.5/327
Figure 6 Schematic representation of UL26 and UL26.5 in the
DEV Clone-03 strain. The location of the R and M cleavage sites
are indicated by the arrows and the dashed lines indicate the
cleavage sites. The results were based on the alignment of the
structure of UL26 in DEV and HSV-1 [36,39]. The sequence of the
epitope is indicated by the yellow bars. Each of the proteins is
designated by UL26 or UL26.5 plus the sites of cleavage. The pink
bars represent the amino acid sequence that contains the epitope
defined by mAb 1C8. The gray bars represent the proteins that
were not recognized by mAb 1C8.
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sequences and locations of the primers used for amplifi-
cation and expression of the gene in this study are
shown in Table 1.
After construction, each recombinant expression con-
struct was transformed into E. coli BL21 (DE3) (Nova-
gen, Gibbstown, NJ, USA). A series of fusion proteins
with the expected molecular weights were induced by
IPTG and stained with Coomassie blue after SDS-PAGE
as described previously [37]. For preparation of purified
proteins, inclusion body proteins were separated by
SDS-PAGE, the proteins of interest were excised, and
the gel slices were crushed and added to an appropriate
volume of sterilized PBS. The extracted proteins were
used for western blotting and ELISA.
Generation of mAbs against the DEV UL26 protein
Three 8-week-old BALB/c mice were primed subcuta-
neously with DEV virus particles mixed with an equal
volume of Freund’s complete adjuvant (Sigma, USA),
followed by two boosts of immunization with the
recombinant protein UL26c. The protocols used for
the preparation of mAbs and ascitic fluid have been
described previously [37,38]. All hybridomas were
cloned by at least three rounds of limiting dilution.
The class and subclass of the mAb produced were
determined using an SBA Clonotyping™ System/HRP
kit (Southern Biotechnology Associates, Birmingham,
USA).
SDS-PAGE and western blotting
The specificity and reactivity of the mAb 1C8 were also
determined by western blotting using recombinant
UL26c protein and CEF infected by DEV, respectively.
Purified recombinant UL26c protein, truncated proteins
and DEV in CEF were separated by denaturing SDS-
PAGE. For western blotting, all the proteins and the
virus were transferred onto nitrocellulose membranes,
and detected as described previously [37]. Purified
recombinant GST (rGST) protein and the CEF were
used as negative antigen controls.
Indirect ELISA
The reactivity of the mAb with different truncated
recombinant UL26 proteins was determined further by
ELISA as described previously [37]. Briefly, the purified
recombinant proteins were used as coating antigens,
applied at 10 μg/well in 0.1 M carbonate buffer (pH 9.6)
at 4°C for 12 h, and blocked with 0.5% BSA at 37°C for
1 h. After washing three times with PBST, 100 μlo f
mAb were added to the wells and incubated at 37°C for
1 h. The plates were washed three times and incubated
with HRP-conjugated sheep anti-mouse secondary anti-
body at 37°C for 1 h. The color was developed and the
Table 1 Sequences of the primers used in this study
Fragments Primer sequences (5’ -3 ’)
a Position in UL26
gene
b
Size of amplicon
(bp)
Sense Negative sense
UL26c GGATCCATGCAATCTACTATGACG GTCGACTCAACATCTATTACACATCA 1042-2124 1083
F1 GGATCCATGCAATCTACTATGACG GTCGACTTACAGCTGCCCTCCCTGGAC 1042-1347 306
F2 GGATCCATGTATGGACAGCCTGTTTAT GTCGACTTAAGCTAATGGTCCAGTAGA 1294-1731 438
F3 GGATCCATGCCTACTGGACAAGGTAAC GTCGACTCAACATCTATTACACATCA 1681-2124 444
F2-1 GGATCCATGTATGGACAGCCTGTTTAT CTTTGGTCGACTTAATCTCCAGATTCGACGGC 1294-1455 162
F2-2 TGCAGGGATCCATGGCAATTGCTGCAGATAGG CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1411-1575 165
F2-3 TGCAGGGATCCATGAATGACGACCAGTTAGAT GTCGACTTAAGCTAATGGTCCAGTAGA 1531-1731 201
F4 TGCAGGGATCCATGAATGACGACCAGTTAGAT CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1531-1575 45
F5 TGCAGGGATCCATGGACGACCAGTTAGATGGT CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1534-1575 42
F6 TGCAGGGATCCATGCAGTTAGATGGTGACAAT CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1540-1575 36
F7 TGCAGGGATCCATGTTAGATGGTGACAATATC CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1543-1575 33
F8 TGCAGGGATCCATGGATGGTGACAATATCTAT CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1546-1575 30
F9 TGCAGGGATCCATGGGTGACAATATCTATTAT CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1549-1575 27
F10 TGCAGGGATCCATGGACAATATCTATTATCCG CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1552-1575 24
F11 TGCAGGGATCCATGAATATCTATTATCCGGGG CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1555-1575 21
F12 TGCAGGGATCCATGATCTATTATCCGGGGGAA CTTTGGTCGACTTATTCCCCCGGATAATAGAT 1558-1575 18
F13 GATCCATGATCTATTATCCGGGGTAAG TCGACTTACCCCGGATAATAGATCATG 1558-1572 15
F14 GATCCATGTATTATCCGGGGGAATAAG TCGACTTATTCCCCCGGATAATACATG 1561-1575 15
a The introduced restriction enzyme sites (Bam HI and Sal I) in each primer are underlined. The stop codon, TCA, of the DEV UL26 gene and the introduced start
and stop codons in the primers of the UL26 fragments are shown in bold, respectively.
b The nucleotide positions correspond to those of the DEV UL26 gene, GenBank accession no. EF203709.
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at 490 nm. All assays were performed in triplicate.
In vitro neutralization test
The mAb 1C8 was tested for the presence of DEV-neutra-
lizing antibodies. The CEF lysates containing DEV were
mixed with ascites fluid containing mAb 1C8 and incu-
bated at 37°C for 1 h; unrelated ascites fluid and PBS, used
as negative controls, were treated in the same way. The
mixture was added to the prepared CEF and incubated at
37°C. After 2 h of incubation, the mixture was removed
and the cells were overlaid with 1% low-melting-point
agarose containing 8% FBS. At 72 h post-incubation, the
cells were overlaid again with 1% low-melting-point agar-
ose containing 0.1% Ponceau. After further incubation at
37°C for 24 h, the plaques were counted and compared.
Detection of the reactivity of the epitope defined by mAb
1C8
To investigate whether the peptides could be recognized
by anti-DEV antibody, the epitope peptide F12 was puri-
fied and used as antigen to coat ELISA plates (10 μg/
well) to react with mouse anti-DEV antibody and mouse
sera, respectively. Purified rGST was used as the nega-
tive control for F12. In addition, the purified F12 and
rGST were also used to detect the reactivity of the
epitope peptide by western blotting.
Homologous analysis of the sequence of the epitope
defined by mAb 1C8
The mAb 1C8-defined epitope sequences and flanking
sequences of DEV were compared with those of 14
other selected herpesviruses of the Alphaherpesvirinae
using the MEGALIGN program in Lasergene (DNAStar)
with CLUSTAL W multiple alignments, as described
previously [23]. The 14 herpesviruses used in this study
were as follows: equine herpesvirus 1 (EHV-1)
(NC_001491), equine herpesvirus 4 (EHV-4)
(AF030027), pseudorabies virus (PRV) (BK001744), vari-
cella-zoster virus (VZV) (NC_001348), bovine herpes-
virus 1 (BHV-1) (AJ004801), bovine herpesvirus 5
(BHV-5) (AY261359), herpes simplex virus type 1
(HSV-1) (X14112), herpes simplex virus type 2 (HSV-2)
(NC_001798), cercopithecine herpesvirus 1 (CeHV-1)
(NC_004812), cercopithecine herpesvirus 2 (CeHV-2)
(NC_006560), Marek’s disease virus 1 (MDV-1)
(AF243438), Marek’sd i s e a s ev i r u s2( M D V - 2 )
(AB049735), turkey herpesvirus (HVT) (AF291866), and
infectious laryngotracheitis virus (ILTV) (NC_006623).
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